{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-029913","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.815929+00:00","generated_at":"2026-06-22T22:10:29.069508+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lineage Cell Therapeutics appoints Jill A. Howe as CFO effective Nov 14, 2022","bullets":["Ms. Howe will receive an annual salary of $415,000 and a $50,000 sign-on bonus.","She is eligible for an annual bonus targeted at 40% of salary and granted a stock option for 1,000,000 shares.","Her prior roles include CFO of DTx Pharma, VP Finance at Gossamer Bio (GOSS), and controller at Amplyx.","CEO Brian Culley and Sr. Director Alexandra Hernandez will step down from interim CFO and principal accounting officer roles.","Ms. Howe also serves on boards of Biora Therapeutics (BIOR) and Codagenix Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-029913","json":"https://secwatch.observer/filing/0001493152-22-029913.json","markdown":"https://secwatch.observer/filing/0001493152-22-029913.md","text":"https://secwatch.observer/filing/0001493152-22-029913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315222029913/0001493152-22-029913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315222029913/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T22:10:29.069508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae0a33960e","claim":"Jill A. Howe was appointed as Chief Financial Officer at Lineage Cell Therapeutics, Inc..","evidence_excerpt":"On October 28, 2022, Lineage Cell Therapeutics, Inc. (“Lineage,” “we,” “us,” “our,” or the “Company”) appointed Jill A. Howe as its Chief Financial Officer, effective November 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222029913/0001493152-22-029913-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}